Description: Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Home Page: cytekbio.com
CTKB Technical Analysis
47215 Lakeview Boulevard
Fremont,
CA
94538
United States
Phone:
877 922 9835
Officers
Name | Title |
---|---|
Dr. Wenbin Jiang Ph.D. | Pres, CEO & Chairman |
Mr. Patrik Sebastian Jeanmonod | Chief Financial Officer |
Dr. Ming Yan Ph.D. | CTO & Director |
Dr. Allen B. Poirson Ph.D. | Sr. VP of Bus. & Corp. Devel. |
Mr. Chris Williams | Chief Operating Officer |
Mr. Mark Edinger | VP of Scientific Affairs |
Mr. Paul D. Goodson | Head of Investor Relations |
Ms. Valerie T. Barnett J.D. | Gen. Counsel & Corp. Sec. |
Ms. Connie Wedel | Chief People Officer |
Mr. Todd Garland | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Forward PE: | 370.3704 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 3.6527 |
Price-to-Sales TTM: | 9.4122 |
IPO Date: | 2021-07-23 |
Fiscal Year End: | December |
Full Time Employees: | 574 |